[1] Li Y, Zhou L, Huang Z, et al. Chinese AIH Consortium. Fine mapping identifies independent HLA associations in autoimmune hepatitis type 1[J]. JHEP Rep,2023,6(1):100926.
[2] Snijders RJ, Stoelinga AE, Gevers TJ, et al. Dutch Autoimmune Hepatitis Working Group. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis[J]. J Hepatol,2023.
[3] Colapietro F, Maisonneuve P, Lytvyak E, et al. Dutch AIH Study Group; International Autoimmune Hepatitis Group. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis[J]. J Hepatol,2023.
[4] Andrade RJ, Aithal GP, de Boer YS, et al. IAIHG and EASL DHILI Consortium. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report[J]. J Hepatol,2023,79(3):853-866.
[5] Li Y, Li Z, Chen R, et al. A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression[J]. Nat Commun,2023,14(1):1732.
[6] Chen R, Huang B, Lian M, et al. A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis[J]. J Hepatol,2023,79(6):1478-1490.
[7] Zhang J, Lyu Z, Li B, et al. P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases[J]. Hepatology,2023,78(1):10-25.
[8] Kowdley KV, Bowlus CL, Levy C, et al. ELATIVE Study Investigators' Group. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis[J]. N Engl J Med,2023.
[9] Hirschfield GM, Shiffman ML, Gulamhusein A, et al. ENHANCE Study Group*. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study[J]. Hepatology,2023,78(2):397-415.
[10] Li Y, Li B, Xiao X, et al. Itaconate inhibits CD103 + T RM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis[J]. Hepatology, 2024,79(1):25-38.
[11] Shaw DG, Aguirre-Gamboa R, Vieira MC, et al. Antigen-driven colonic inflammation is associated with development of dysplasia in primary sclerosing cholangitis[J]. Nat Med,2023,29(6):1520-1529.
[12] Villard C, Friis-Liby I, Rorsman F, et al. Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis[J]. J Hepatol,2023,78(3):604-613. |
